TechSeeker Profile

Ribozyme Pharmaceuticals (AKA: Sirna Therapeutics)
Profile last edited on: 9/10/2013

Develops therapeutics based on RNA interference (RNAi) technology.
TS Type
Year Founded
Last Involved Year

Key People / Management

  Roberto Guerciolini -- Chief Medical Officer and Senior Vice President of Development

  Kathryn Prickett -- Senior Director of Business Development

Location Information

185 Berry Street Suite 6504
San Francisco, CA 94107
   (415) 512-7200

Public Profile

Sirna Therapeutics, Inc., a biotechnology company, develops therapeutics based on RNA interference (RNAi) technology. It engages in the research, preclinical, and/or clinical development with product candidates in the various areas, including age-related macular degeneration (AMD), chronic hepatitis, dermatology, asthma, Huntington's disease (HD), oncology, and diabetes. The company offers Sirna-027, which completed phase I clinical trial is used for the treatment of AMD; Sirna-034, which is under preclinical stage is used for the treatment of hepatitis C virus; and various drugs under preclinical stage of development for asthma, HD, chronic hepatitis, diabetes, and dermatology. It has strategic alliances with Allergan, Inc., Eli Lilly and Company, Targeted Genetics, Protiva, Archemix Corporation, and GlaxoSmithKline. The company, formerly known as Ribozyme Pharmaceuticals, Inc., was founded in 1992 and changed its name to Sirna Therapeutics, Inc. in 2003. Sirna Therapeutics is headquartered in San Francisco, California. As of December 29, 2006 Sirna Therapeutics, Inc. operates as a subsidiary of Merck & Co., Inc.

Extent of SBIR involvement

User Avatar

Synopsis: Techseeker Business Condition

Privately Held
Stock Info
Received SBIR $$

Techseeker firm in the news

There are no news available.